Recordati

Recordati, founded in 1926, has established itself as a significant player in the global pharmaceutical landscape. Headquartered in Italy, this company is deeply rooted in a century-long tradition of developing life-enhancing and life-changing medicines.

With over 4,500 employees, Recordati operates in around 150 countries, focusing on both common and rare diseases. This extensive reach aligns with its mission of providing health as a universal right.

Publicly listed on the Italian stock exchange, Recordati recently secured a substantial €600.00M in Post Ipo Equity investment as of 01 February 2025, reflecting investor confidence in its ability to innovate in pharmaceuticals. While specific investor details remain undisclosed, the funding underlines the company's commitment to leveraging new ideas and technologies to combat diseases.

In summary, Recordati exemplifies a robust blend of heritage and innovation, striving to "Unlock the full potential of life" through its continued excellence in the pharmaceutical industry.